Comments
Strides Pharma Sciences Limited has posted ₹101.84 crore profit for the first-quarter of 2020-21 as against ₹2.91 crore posted last year.
The company’s revenue was up 14.08 per cent for Q1 at ₹794.10 crore as against ₹696.05 crore posted last year. EPS for the quarter stood at ₹11.56 compared with ₹3.11 last year.
Commenting on the performance, R Ananthanarayanan, Managing Director & CEO, saud, “Coming out of a challenging Q4 FY20 due to Ranitidine withdrawal, Strides has started FY21 on a positive note. We have reported strong performance across all our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment due to Covid-19.”
He added “Our regulated markets growth was 22 per cent quarter-on-quarter and our emerging markets are now returning to growth after several quarters.”
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.